Core Viewpoint - Koyuan Pharmaceutical (301281.SZ) expects a significant decline in net profit for 2025, projecting a range of 27.20 million to 39.29 million yuan, representing a decrease of 35% to 55% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 27.20 million and 39.29 million yuan, reflecting a year-on-year decline of 35% to 55% [1] - The net profit after deducting non-recurring gains and losses is estimated to be between 20.12 million and 29.06 million yuan, also indicating a decrease of 35% to 55% year-on-year [1] Operational Changes - The company is intensifying its efforts in the formulation market, which has led to an increase in sales expenses [1] - Based on actual circumstances and accounting standards, the company has conducted a comprehensive review of various receivables and other assets, adhering to principles of prudence and reasonableness [1] - The company plans to make provisions for asset impairment losses on assets that may incur such losses, resulting in an increase in asset impairment losses [1]
科源制药(301281.SZ)：预计2025年净利润同比下降35%-55%